Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents and Intangibles - Additional Information (Detail)

v3.20.2
Acquisition of Patents and Intangibles - Additional Information (Detail) - USD ($)
 3 Months Ended
Oct. 16, 2012
Aug. 31, 2020
Aug. 31, 2019
Jun. 29, 2020
May 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]          
Intangible asset acquired gross   $ 3,500,000 $ 3,500,000   $ 3,500,000
Estimated aggregate future amortization expense in next twelve months   2,000,000.0      
Estimated aggregate future amortization expense in year two   1,500,000      
Estimated aggregate future amortization expense in year three   1,100,000      
Estimated aggregate future amortization expense in year four   1,000,000.0      
Estimated aggregate future amortization expense in year five   $ 1,000,000.0      
Issuance of common stock shares   570,325,000   4,000,000 519,261,000
Common stock per shares   $ 0.001     $ 0.001
ProstaGene, LLC          
Acquired Finite-Lived Intangible Assets [Line Items]          
Acquisition of ProstaGene LLC, value   $ 11,558,000      
Issuance of common stock shares   20,278,000      
Common stock per shares   $ 0.57      
ProstaGene, LLC | Dr .Pestell | Stock Restriction Agreement          
Acquired Finite-Lived Intangible Assets [Line Items]          
Restricted common stock, shares   8,342,000      
Common stock shares restriction period   3 years      
Stock repurchase price, per share   $ 0.001      
ProstaGene, LLC | Investment Advisory, Management and Administrative Service          
Acquired Finite-Lived Intangible Assets [Line Items]          
Investment earned shares   1,620,000      
Patents          
Acquired Finite-Lived Intangible Assets [Line Items]          
Asset purchase, cash paid $ 3,500,000        
Estimated useful life of acquired asset   10 years      
Amortization expense related to acquired patents   $ 500,000 $ 500,000